Zymeworks Inc. announced on November 5, 2024, that the first patient has been dosed in its first-in-human Phase 1 trial (NCT06555744) evaluating the investigational therapy ZW191. This trial focuses on the safety and tolerability of ZW191 in patients with advanced folate receptor-⍺ (FRα)-expressing solid tumors, including ovarian, endometrial, and non-small cell lung (NSCLC) cancers.
ZW191 is an antibody-drug conjugate (ADC) that utilizes Zymeworks' novel proprietary payload, ZD06519. Preclinical data presented earlier in 2024 at the American Association for Cancer Research (AACR) Annual Meeting indicated that ZW191 was associated with greater anti-tumor activity compared to benchmarks in FRα-expressing tumor models and was well-tolerated in cynomolgus monkeys up to 60 mg/kg.
The initiation of this global study represents a significant milestone for Zymeworks, as it advances another promising therapy from its wholly-owned pipeline into clinical development. This follows the recent initiation of the Phase 1 trial for ZW171, further demonstrating the company's commitment to developing innovative therapies for patients with high unmet medical needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.